Integrated CDMO Alliance Targets Oral Drug Timelines

Bora Pharmaceuticals and Corealis Pharma align development and manufacturing to streamline oral solid dose drug programs and reduce delays for sponsors

10 Feb 2026

Bora Pharmaceuticals and Corealis Pharma have formed a strategic alliance to speed the development of oral solid dose medicines, a category that still accounts for most prescriptions globally.

The partnership aims to address a common bottleneck in pharmaceutical development, namely the handover between formulation, clinical supply and commercial manufacturing. Sponsors typically rely on several external providers across these stages, increasing the risk of delays, higher costs and technical problems.

Under the alliance, Corealis will focus on early stage formulation development and clinical trial supply, while Bora will provide large scale manufacturing and regulatory support. The companies said closer alignment at the outset would help ensure that products designed for clinical trials can be manufactured efficiently at commercial scale.

Executives from both groups have argued that decisions made during formulation often determine later success or failure. By linking development and manufacturing earlier, they said, sponsors could reduce rework and shorten timelines.

The collaboration reflects a broader shift in the contract development and manufacturing organisation, or CDMO, market. Drug pipelines are increasingly crowded, and competition has intensified pressure on developers to move quickly without weakening quality standards. As a result, sponsors are seeking partners that can support multiple stages of a product’s lifecycle rather than isolated tasks.

Integrated CDMO models are particularly attractive to small and mid sized biotechnology companies, which often lack the internal resources to manage several vendors at once. A single, coordinated alliance can reduce operational risk and allow teams to focus on advancing their research.

Service providers also stand to benefit from earlier visibility into projects, which can improve planning and strengthen long term relationships with clients.

Supporters of the model acknowledge that tighter integration requires robust quality systems and frequent communication. They argue, however, that closer coordination makes potential issues easier to identify and resolve.

As cost pressures rise across the industry, alliances such as that between Bora and Corealis suggest a move towards more streamlined development of oral solid dose medicines, with fewer handovers and shorter paths to market.